These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 29898842)

  • 1. Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure.
    Luo N; Ballew NG; O'Brien EC; Greiner MA; Peterson PN; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Mentz RJ; Fonarow GC
    Am Heart J; 2018 Jun; 200():134-140. PubMed ID: 29898842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).
    Luo N; Fonarow GC; Lippmann SJ; Mi X; Heidenreich PA; Yancy CW; Greiner MA; Hammill BG; Hardy NC; Turner SJ; Laskey WK; Curtis LH; Hernandez AF; Mentz RJ; O'Brien EC
    JACC Heart Fail; 2017 Apr; 5(4):305-309. PubMed ID: 28359417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Hospital Characteristics and Early Adoption of Angiotensin-Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure.
    Luo N; Lippmann SJ; Mentz RJ; Greiner MA; Hammill BG; Hardy NC; Laskey WK; Heidenreich PA; Chang CL; Hernandez AF; Curtis LH; Peterson PN; Fonarow GC; O'Brien EC
    J Am Heart Assoc; 2019 Feb; 8(3):e010484. PubMed ID: 30712431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Insurance Status and Region on Angiotensin Receptor-Neprilysin Inhibitor Prescription During Heart Failure Hospitalizations.
    Davogustto G; Wells QS; Harrell FE; Greene SJ; Roden DM; Stevenson LW
    JACC Heart Fail; 2024 May; 12(5):864-875. PubMed ID: 38639698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction.
    Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK
    Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
    Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
    Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.
    Fonarow GC; Hernandez AF; Solomon SD; Yancy CW
    JAMA Cardiol; 2016 Sep; 1(6):714-7. PubMed ID: 27437874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the clinical and budgetary impact of using angiotensin receptor neprilysin inhibitor as first line therapy in patients with HFrEF.
    Bergh N; Lindmark K; Lissdaniels J; Lanne G; Käck O; Cowie MR
    ESC Heart Fail; 2024 Apr; 11(2):1153-1162. PubMed ID: 38279516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is New in Heart Failure Management in 2017? Update on ACC/AHA Heart Failure Guidelines.
    Bozkurt B
    Curr Cardiol Rep; 2018 Apr; 20(6):39. PubMed ID: 29667019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
    Mareev YV; Mareev VY
    Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.
    Mukhopadhyay A; Reynolds HR; Nagler AR; Phillips LM; Horwitz LI; Katz SD; Blecker S
    BMC Cardiovasc Disord; 2022 Aug; 22(1):354. PubMed ID: 35927632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ARNI, new abbreviation for a new class of treatment of heart failure].
    Karimzadeh S; Mustafić H; Stampfli Andres T
    Rev Med Suisse; 2017 Mar; 13(552):496-499. PubMed ID: 28714615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.
    Komajda M; Cowie MR; Tavazzi L; Ponikowski P; Anker SD; Filippatos GS;
    Eur J Heart Fail; 2017 Nov; 19(11):1414-1423. PubMed ID: 28463464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
    Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
    Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
    Khazanie P; Liang L; Curtis LH; Butler J; Eapen ZJ; Heidenreich PA; Bhatt DL; Peterson ED; Yancy CW; Fonarow GC; Hernandez AF
    Circ Heart Fail; 2016 Feb; 9(2):e002444. PubMed ID: 26867758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in provider approach to initiating and titrating guideline directed medical therapy in heart failure with reduced ejection fraction.
    Cordwin DJ; Guidi J; Alhashimi L; Hummel SL; Koelling TM; Dorsch MP
    BMC Cardiovasc Disord; 2024 May; 24(1):247. PubMed ID: 38730379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: Results from TSOC-HFrEF registry.
    Chang HY; Wang CC; Wei J; Chang CY; Chuang YC; Huang CL; Chong E; Lin JL; Mar GY; Chan KC; Kuo JY; Wang JH; Chen ZC; Tseng WK; Cherng WJ; Yin WH
    J Chin Med Assoc; 2017 Dec; 80(12):750-757. PubMed ID: 29033112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.
    Maizels L; Wasserstrum Y; Fishman B; Segev A; Ben-Nun D; Younis A; Freimark D; Mazin I; Grupper A
    ESC Heart Fail; 2022 Jun; 9(3):1682-1688. PubMed ID: 35178886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care.
    Desai RJ; Patorno E; Vaduganathan M; Mahesri M; Chin K; Levin R; Solomon SD; Schneeweiss S
    Heart; 2021 Sep; 107(17):1407-1416. PubMed ID: 34088766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.